enGene Therapeutics (ENGN) Accounts Payables (2022 - 2026)

enGene Therapeutics (ENGN) has 5 years of Accounts Payables data on file, last reported at $2.5 million in Q3 2026.

• For the quarter ending Q3 2026, Accounts Payables rose 6.59% year-over-year to $2.5 million; the trailing twelve-month figure through Jul 2026 stood at $2.5 million (up 6.59% YoY), and the FY2025 full-year result was $6.7 million, up 373.99% from the prior year.
• Accounts Payables was $2.5 million for Q3 2026 at enGene Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.7 million in Q4 2025 to a low of $211000.0 in Q2 2024.
• A 5-year average of $2.1 million and a median of $1.8 million in 2026 frame the typical range for Accounts Payables.
• The largest YoY upside for Accounts Payables was 642.65% in 2025 against a maximum downside of 16.7% in 2025.
• enGene Therapeutics' Accounts Payables stood at $723000.0 in 2022, then soared by 59.89% to $1.2 million in 2023, then climbed by 22.06% to $1.4 million in 2024, then surged by 373.99% to $6.7 million in 2025, then sank by 62.01% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.5 million in Q3 2026, $1.8 million in Q2 2026, and $2.4 million in Q1 2026.